|Application No.||Application Title||Issue Date|
|20140051712||BLOOD BRAIN BARRIER-PENETRATING OXIMES FOR CHOLISTENERASES REACTIVATION|
The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase...
|20140051855||PENTA-SUBSTITUTED TETRAHYDROPYRIMIDINES WITH AGGREGATION-INDUCED EMISSION CHARACTERISTICS AND PREPARATION METHOD AND USE THEREOF|
The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R
|20140031373||PYRIMIDINE DERIVATIVES AND USE THEREOF AS PESTICIDES|
The present invention relates to novel substituted pyrimidine derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in c...
|20140031370||AMIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS INSECTICIDE|
A compound represented by Formula (1):
|20140021406||LIQUID CRYSTAL COMPOUND HAVING FLUOROVINYL GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE|
A liquid crystal compound having a high stability to heat, light and so forth, a high clearing point, a low minimum temperature of a liquid crystal phase, a small viscosity, a suitable optical anisotropy, a large dielectric anisotropy, a suitable elastic constant and an...
|20140018326||SULFONAMIDES AS HIB PROTEASE INHIBITORS|
Compounds of Formula I are disclosed: wherein L, A, R1, R2, R3A, R3B, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds ...
|20140018368||HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES|
The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer....
In one aspect, the invention relates to compounds having the formula:
where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These c...
The present invention relates to 1-[m-Carboxamido(hetero)aryl-methyl]-piperidine-4-carboxamide derivatives of formula (I)
wherein X, Ar1, R1, R2, R3, R4,...
|20130310379||MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF|
Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein....
|20130303549||NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF|
Novel biaromatic compounds having the general formula (I):
and cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardi...
|20130296322||SEROTONIN REUPTAKE INHIBITORS|
In one aspect, the invention relates to compounds of formula I:
where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound...
|20130261122||Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors|
The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same....
|20130261135||METALLOENZYME INHIBITOR COMPOUNDS|
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes....
|20130261305||PROCESS OF MAKING GYRASE AND TOPOISOMERASE INHIBITORS|
The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I)
or a pharmaceutically acceptable salts thereof, wherein R is H or F, and each of R3
|20130245018||Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use|
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also ...
The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds....
|20130228720||CHIRAL COMPOUNDS, CHOLESTERIC AND FERROELECTRIC LIQUID CRYSTAL COMPOSITIONS COMPRISING THESE CHIRAL COMPOUNDS, AND LIQUID CRYSTAL DISPLAYS COMPRISING THESE LIQUID CRYSTAL COMPOSITIONS|
Chiral liquid crystal compounds of the general formula (1):
|20130231479||ARYLOXYUREA COMPOUND AND PEST CONTROL AGENT|
The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each ind...
|20130203727||NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS|
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compo...
|20130197011||Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament|
Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders....
|20130197013||CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS|
The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
|20130184263||Derivatives of Betulin|
The present invention relates to compounds characterized by having a structure according to the following Formula I:
or a pharmaceutically acceptable salt thereof. Compounds of the present invention are usefu...
|20130178420||NOVEL GLP-1 RECEPTOR MODULATORS|
The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or w...
|20130172558||NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS|
Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compounds, which can be used in liquid crystal compositions useful for electro-optical and display device applications. The liquid crystal can be a ferroelectric liquid crystal. Also prov...
|20130172316||New azetidine derivatives, pharmaceutical compositions and uses thereof|
The invention relates to new azetidine derivatives of the formula I
to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them....
|20130165422||HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION|
The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I):
The present invention relates to a compound of formula I
wherein R1, R2, and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to ...
|20130150579||NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS|
The present invention provides a process for preparing novel intermediates of Formula wherein, R1 can be hydrogen, C1-C4 alkyl, halogen, nitro, hydroxy, or C1-C4 alkoxy; Rx can be selected from hydrophobi...
|20130136794||HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF|
Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the descript...
|20130131036||NOVEL TRPV3 MODULATORS|
Disclosed herein are modulators of TRPV3 of formula (II):
wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u a...
The present invention relates to the compounds of general formula I
wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9
|20130123254||PHARMACEUTICALLY ACCEPTABLE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND THEIR METHODS OF IDENTIFICATION|
The present invention relates to mGluR5 positive allosteric modulators (PAM) and methods for identifying pharmaceutically acceptable compounds with high tolerability and safety, which method comprises the use of at least one non-competitive mGluR5 allosteric modulator w...
The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial...
|20130109685||1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS|
The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I),
wherein X, Y, Z, n, R1, R2, R3, R4, R5, R6,...
|20130102609||BIARYL OXYACETIC ACID COMPOUNDS|
The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general formula I:
The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof.
The present invention relates to a compound represented by the formula
Disclosed are electroluminescent devices that comprise organic layers that contain certain organic compounds containing one or more pyrimidine moieties. The organic compounds containing one or more pyrimidine moieties are suitable components of blue-emitting, durable, o...
|20130045972||GLUCOCORTICOID RECEPTOR ANTAGONISTS|
The present invention relates to compounds of formula I
wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acc...
|20130023539||PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43)|
The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases....